William Gregory

Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada.

Part of Lumos Pharma, Inc., BioProtection Systems Corp. is a company that manufactures biological products. The company is based in Ames, IA.

Part of Incyte Corp., Maxia Pharmaceuticals, Inc. develops pharmaceutical products based on molecule drug discovery techniques. The company is based in San Diego, CA. The company was founded by David Perryman, Xian Ping Lu. Maxia Pharmaceuticals was acquired by Incyte Corp. on February 19, 2003 for $42.30 million.

Healthios Capital Markets LLC provides financial advisory services. The private company is based in Northbrook, IL and has subsidiaries in Thailand and Singapore. The company was founded by Fritz Reichenbach.

TheraFuse, Inc. designs and develops non-contact optical flow sensors for use in the commercial, industrial and medical applications. It offers delivery systems for insulin, pain medication, and protein drugs, disposable insulin patches for diabetics; and sprinkler hypodermic needles for sub-Q fluid delivery in drug pens. The company was founded in 2001 and is headquartered in Carlsbad, CA.

LaSalle Investments, Inc. operates as a principal investment firm. The company was founded in 1978 by Robert T. Geras and is headquartered in Chicago, IL.

IGL Pharma, Inc. provides health care services. The company was founded in 2016 by Keith R. Frank and Jamie Simon and is headquartered in Angleton, TX.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA.

SynVivo, Inc. is an American company that specializes in microfluidic organ-on-chip technology. The private company's platform allows for the real-time study of cellular behavior, drug delivery, and drug discovery.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.